RNF217

Summary

RNF217 (ring finger protein 217, HGNC:21487) is a protein-coding gene on chromosome 6q22.31, encoding E3 ubiquitin-protein ligase RNF217 (Q8TC41). E3 ubiquitin-protein ligase which accepts ubiquitin from E2 ubiquitin-conjugating enzymes in the form of a thioester and then directly transfers the ubiquitin to targeted substrates.

This protein encoded by this gene is a member of the RING1-IBR-RING24 (RBR) ubiquitin protein ligase family, and it belongs to a subfamily of these proteins that contain a transmembrane domain. This protein can interact with the HAX1 anti-apoptotic protein via its C-terminal RING finger motif, which suggests a role in apoptosis signaling. It is thought that deregulation of this gene can be a mechanism in leukemogenesis. Mutations in the region encoding the protein GXXXG motif, which appears to be necessary for protein self-association, have been found in human cancers. Alternative splicing of this gene results in multiple transcript variants.

Source: NCBI Gene 154214 — RefSeq curated summary.

At a glance

• GWAS associations: 1
• Clinical variants (ClinVar): 33 total
• MANE Select transcript: NM_001286398

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:21487
Approved symbol	RNF217
Name	ring finger protein 217
Location	6q22.31
Locus type	gene with protein product
Status	Approved
Aliases	MGC26996, dJ84N20.1
Ensembl gene	ENSG00000146373
Ensembl biotype	protein_coding
OMIM	618592
Entrez	154214

Gene structure

Transcript identifiers

Ensembl transcripts: 11 — 5 protein_coding, 3 protein_coding_CDS_not_defined, 2 nonsense_mediated_decay, 1 retained_intron

ENST00000359704, ENST00000368414, ENST00000368415, ENST00000431104, ENST00000432158, ENST00000454842, ENST00000519565, ENST00000519799, ENST00000519971, ENST00000521654, ENST00000560949

RefSeq mRNA: 2 — MANE Select: NM_001286398 NM_001286398, NM_152553

CCDS: CCDS5129, CCDS69191

Canonical transcript exons

ENST00000521654 — 6 exons

Exon	Start	End
ENSE00002569703	124962437	124963426
ENSE00003471744	125057942	125058106
ENSE00003509438	125082864	125092633
ENSE00003544547	125081436	125081507
ENSE00003567148	125076657	125076858
ENSE00003580490	125045211	125045444

Expression profiles

Bgee: expression breadth ubiquitous, 233 present calls, max score 92.06.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 9.1017 / max 416.8306, expressed in 1587 samples.

FANTOM5 promoters (18 alternative TSS)

Promoter ID	TPM avg	Samples expressed
69616	2.0509	1001
69618	1.4921	806
69622	1.3924	770
69623	1.2531	518
69620	0.6682	394
69617	0.6321	334
69624	0.3498	160
69619	0.3401	137
69625	0.1879	73
69626	0.1795	45

Top tissues by expression

243 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
oviduct epithelium	UBERON:0004804	92.06	gold quality
upper leg skin	UBERON:0004262	88.83	gold quality
left ovary	UBERON:0002119	88.10	gold quality
upper arm skin	UBERON:0004263	87.87	gold quality
right ovary	UBERON:0002118	87.85	gold quality
calcaneal tendon	UBERON:0003701	87.59	gold quality
ascending aorta	UBERON:0001496	86.82	gold quality
popliteal artery	UBERON:0002250	86.79	gold quality
tibial artery	UBERON:0007610	86.78	gold quality
aorta	UBERON:0000947	86.64	gold quality
thoracic aorta	UBERON:0001515	86.56	gold quality
skin of hip	UBERON:0001554	86.54	gold quality
skin of abdomen	UBERON:0001416	86.47	gold quality
colonic epithelium	UBERON:0000397	86.20	gold quality
ovary	UBERON:0000992	86.16	gold quality
right uterine tube	UBERON:0001302	86.12	gold quality
sperm	CL:0000019	85.77	gold quality
right lung	UBERON:0002167	85.70	gold quality
descending thoracic aorta	UBERON:0002345	85.58	gold quality
fallopian tube	UBERON:0003889	85.39	gold quality
omental fat pad	UBERON:0010414	85.33	gold quality
muscle layer of sigmoid colon	UBERON:0035805	85.33	gold quality
peritoneum	UBERON:0002358	85.31	gold quality
tibia	UBERON:0000979	85.29	gold quality
adipose tissue of abdominal region	UBERON:0007808	85.03	gold quality
left coronary artery	UBERON:0001626	84.95	gold quality
cartilage tissue	UBERON:0002418	84.63	gold quality
zone of skin	UBERON:0000014	84.56	gold quality
tibialis anterior	UBERON:0001385	84.53	gold quality
tibial nerve	UBERON:0001323	84.21	gold quality

Single-cell (SCXA)

Detected in 1 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	6.14

Regulation

Is transcription factor: no

miRNA regulators (miRDB)

457 targeting RNF217, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4262	100.00	73.26	3931
HSA-MIR-3163	100.00	77.23	8605
HSA-MIR-8485	100.00	77.57	4731
HSA-MIR-190A-3P	100.00	80.35	5520
HSA-MIR-5011-5P	100.00	83.46	5820
HSA-MIR-432-3P	100.00	67.86	705
HSA-MIR-5692A	100.00	74.40	6850
HSA-MIR-1277-5P	100.00	73.95	5056
HSA-MIR-340-5P	100.00	72.50	4437
HSA-MIR-3613-3P	100.00	76.36	7965
HSA-MIR-656-3P	100.00	72.15	2788
HSA-LET-7A-3P	100.00	74.03	3932
HSA-MIR-5692B	100.00	71.32	2622
HSA-MIR-5692C	100.00	71.32	2622
HSA-LET-7F-1-3P	100.00	74.02	3928
HSA-MIR-3646	100.00	73.56	5283
HSA-MIR-450A-1-3P	100.00	69.33	1837
HSA-LET-7B-3P	100.00	74.08	3913
HSA-MIR-98-3P	100.00	74.08	3907
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-7110-3P	100.00	73.18	2486
HSA-MIR-4692	100.00	67.32	2066
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4668-3P	100.00	68.74	2635
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4510	100.00	66.60	2050
HSA-MIR-6127	100.00	66.76	2188
HSA-MIR-6129	100.00	66.46	2080
HSA-MIR-6130	100.00	66.69	2012

Literature-anchored findings (GeneRIF, showing 1)

• The high expression of RNF217 in certain human leukemias suggests that the deregulation of this gene could be a more common mechanism in leukemogenesis. (PMID:25298122)

Cross-species orthologs

5 orthologs

Organism	Symbol	Gene ID
danio_rerio	rnf217	ENSDARG00000060944
mus_musculus	Rnf217	ENSMUSG00000063760
rattus_norvegicus	Rnf217	ENSRNOG00000013323
caenorhabditis_elegans		WBGENE00015926
caenorhabditis_elegans		WBGENE00021721

Paralogs (9): ANKIB1 (ENSG00000001629), RNF14 (ENSG00000013561), RNF19A (ENSG00000034677), RNF19B (ENSG00000116514), RNF144B (ENSG00000137393), RNF144A (ENSG00000151692), ARIH1 (ENSG00000166233), ARIH2 (ENSG00000177479), PRKN (ENSG00000185345)

Protein

Protein identifiers

E3 ubiquitin-protein ligase RNF217 — Q8TC41 (reviewed: Q8TC41)

Alternative names: IBR domain-containing protein 1, Opposite STL, RING finger protein 217

All UniProt accessions (5): Q8TC41, E5RFY6, H0YB95, H0YKH8, H3BM17

UniProt curated annotations — full annotation on UniProt →

Function. E3 ubiquitin-protein ligase which accepts ubiquitin from E2 ubiquitin-conjugating enzymes in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. Mediates the degradation of the iron exporter ferroportin/SLC40A1 and thus regulates iron homeostasis.

Subunit / interactions. Interacts with HAX1.

Subcellular location. Membrane. Cytoplasm.

Tissue specificity. Mainly expressed in testis and skeletal muscle.

Domain organisation. Members of the RBR family are atypical E3 ligases. They interact with the E2 conjugating enzyme UBE2L3 and function like HECT-type E3 enzymes: they bind E2s via the first RING domain, but require an obligate trans-thiolation step during the ubiquitin transfer, requiring a conserved cysteine residue in the second RING domain.

Pathway. Protein modification; protein ubiquitination.

Similarity. Belongs to the RBR family. RNF217 subfamily.

Isoforms (2)

UniProt ID	Names	Canonical?
Q8TC41-1	1	yes
Q8TC41-2	2

RefSeq proteins (2): NP_001273327, NP_689766 (=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR002867	IBR_dom	Domain
IPR013083	Znf_RING/FYVE/PHD	Homologous_superfamily
IPR031127	E3_UB_ligase_RBR	Family
IPR044066	TRIAD_supradom	Domain
IPR047550	RNF217_RBR_vRING-HC	Domain
IPR047551	BRcat_RBR_RNF217	Domain
IPR047552	Rcat_RBR_RNF217	Domain

Pfam: PF01485, PF22191

UniProt features (32 total): binding site 16, compositionally biased region 4, zinc finger region 3, region of interest 3, splice variant 2, chain 1, transmembrane region 1, active site 1, sequence variant 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q8TC41-F1	62.43	0.06

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Catalytic / active sites (1): 436

Ligand- & substrate-binding residues (16): 263; 266; 283; 286; 383; 386; 391; 396; 423; 426; 441; 444 …

Function

Pathways and Gene Ontology

Reactome pathways

4 pathways

ID	Pathway
R-HSA-983168	Antigen processing: Ubiquitination & Proteasome degradation
R-HSA-1280218	Adaptive Immune System
R-HSA-168256	Immune System
R-HSA-983169	Class I MHC mediated antigen processing & presentation

MSigDB gene sets: 197 (showing top): REACTOME_ADAPTIVE_IMMUNE_SYSTEM, TGCTGCT_MIR15A_MIR16_MIR15B_MIR195_MIR424_MIR497, REACTOME_CLASS_I_MHC_MEDIATED_ANTIGEN_PROCESSING_PRESENTATION, REACTOME_ANTIGEN_PROCESSING_UBIQUITINATION_PROTEASOME_DEGRADATION, GOBP_MACROMOLECULE_CATABOLIC_PROCESS, GOBP_POST_TRANSLATIONAL_PROTEIN_MODIFICATION, GOBP_PROTEIN_CATABOLIC_PROCESS, RODRIGUES_THYROID_CARCINOMA_POORLY_DIFFERENTIATED_DN, GOCC_TRANSFERASE_COMPLEX, GOBP_PROTEOLYSIS, GOMF_ACYLTRANSFERASE_ACTIVITY, chr6q22, GOCC_UBIQUITIN_LIGASE_COMPLEX, GOMF_AMINOACYLTRANSFERASE_ACTIVITY, GOMF_UBIQUITIN_LIKE_PROTEIN_CONJUGATING_ENZYME_BINDING

GO Biological Process (2): ubiquitin-dependent protein catabolic process (GO:0006511), protein ubiquitination (GO:0016567)

GO Molecular Function (6): ubiquitin-protein transferase activity (GO:0004842), zinc ion binding (GO:0008270), ubiquitin conjugating enzyme binding (GO:0031624), ubiquitin protein ligase activity (GO:0061630), transferase activity (GO:0016740), metal ion binding (GO:0046872)

GO Cellular Component (4): ubiquitin ligase complex (GO:0000151), cytoplasm (GO:0005737), cytosol (GO:0005829), membrane (GO:0016020)

Reactome top-level categories

Rollup of top-3 pathways:

Category	Pathways
Class I MHC mediated antigen processing & presentation	1
Immune System	1
Adaptive Immune System	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
cellular anatomical structure	3
protein ubiquitination	1
modification-dependent protein catabolic process	1
protein modification by small protein conjugation	1
ubiquitin-like protein transferase activity	1
transition metal ion binding	1
ubiquitin-like protein conjugating enzyme binding	1
ubiquitin-protein transferase activity	1
ubiquitin-like protein ligase activity	1
catalytic activity	1
cation binding	1
intracellular protein-containing complex	1
transferase complex	1
intracellular anatomical structure	1
cytoplasm	1

Protein interactions and networks

STRING

584 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
RNF217	SLC35E3	Q7Z769	486
RNF217	HAX1	O00165	480
RNF217	TTC13	Q8NBP0	461
RNF217	SLCO5A1	Q9H2Y9	453
RNF217	RNF19B	Q6ZMZ0	418
RNF217	DCXR	Q7Z4W1	412
RNF217	RALB	P11234	392
RNF217	PCMTD1	Q96MG8	386
RNF217	ABTB3	A6QL63	384
RNF217	FBXO32	Q969P5	380
RNF217	TRIML1	Q8N9V2	367
RNF217	RNF19A	Q9NV58	362
RNF217	UBE2O	Q9C0C9	360
RNF217	MAP2K3	P46734	355
RNF217	MYOCD	Q8IZQ8	354

IntAct

3 interactions, top by confidence:

A	B	Type	Score
RNF217	ACTA2	psi-mi:“MI:0914”(association)	0.530

BioGRID (22): HAX1 (Two-hybrid), RNF217 (Reconstituted Complex), RNF217 (Affinity Capture-Western), POTEKP (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), H1FNT (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), POTEKP (Affinity Capture-MS), ACTA2 (Affinity Capture-MS), ACTBL2 (Affinity Capture-MS), RNF217 (Two-hybrid), RNF217 (Affinity Capture-Western), SLC40A1 (Affinity Capture-Western), RNF217 (Affinity Capture-MS), RNF217 (Affinity Capture-MS)

ESM2 similar proteins: A0A494C0Z2, A0A494C191, A1L3C1, A2RRU4, A4Q9F3, A6NJR5, A6NLX3, A6NNV3, A6QM06, A6QNT4, D4A6L0, E1BBQ2, E9PGG2, O00255, O60320, O88559, P0DTA3, P0DUD1, P0DUD2, P0DUD3, P0DUD4, P0DUX0, P0DUX1, P0DV79, P29590, P40338, P56726, P97260, Q0P5I0, Q12770, Q14094, Q32L49, Q495Y7, Q5IBH6, Q5MJ68, Q5MNU5, Q5Q9Z2, Q5RDC3, Q5T848, Q69Z89

Diamond homologs: D3YYI7, F4KGU4, O95376, Q4KLT0, Q5UQ35, Q6GZQ2, Q8TC41, A1Z9L3, A2A4P0, A2VEA3, F4I9Q5, F4IE66, F4IJV4, F4ILR7, F4IM84, F4JMJ3, F4JRJ6, F4K2E9, O01965, O17438, O22243, O22899, O35286, O42643, O42945, O43143, O45244, O60231, O76924, O94536, P0CE10, P15938, P20095, P24384, P34498, P36009, P37024, P43329, P45018, P53131

SIGNOR signaling

1 interactions.

A	Effect	B	Mechanism
Ub:E2	“up-regulates activity”	RNF217	ubiquitination

Disease & clinical

Clinical variants and AI predictions

ClinVar

33 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	27
Likely benign	0
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

2987 predictions. Top by Δscore:

Variant	Effect	Δscore
6:124964851:G:T	donor_gain	1.0000
6:124996654:GT:G	donor_gain	1.0000
6:125045202:A:AG	acceptor_gain	1.0000
6:125045206:TGCA:T	acceptor_loss	1.0000
6:125045207:GCAG:G	acceptor_loss	1.0000
6:125045208:CAGG:C	acceptor_loss	1.0000
6:125045209:AGG:A	acceptor_loss	1.0000
6:125045210:G:A	acceptor_loss	1.0000
6:125057937:CACA:C	acceptor_loss	1.0000
6:125057939:C:G	acceptor_gain	1.0000
6:125057939:CA:C	acceptor_loss	1.0000
6:125057940:A:AG	acceptor_gain	1.0000
6:125057940:AG:A	acceptor_loss	1.0000
6:125057941:G:GG	acceptor_gain	1.0000
6:125057941:G:T	acceptor_loss	1.0000
6:125081165:G:GG	donor_gain	1.0000
6:124963423:CCAGG:C	donor_loss	0.9900
6:124963424:CAGG:C	donor_loss	0.9900
6:124963425:AGGT:A	donor_loss	0.9900
6:124963426:GG:G	donor_loss	0.9900
6:124963427:G:GC	donor_loss	0.9900
6:124963428:T:G	donor_loss	0.9900
6:125004344:T:G	donor_gain	0.9900
6:125045190:A:AG	acceptor_gain	0.9900
6:125045190:ATCT:A	acceptor_gain	0.9900
6:125045191:T:G	acceptor_gain	0.9900
6:125045193:T:TA	acceptor_gain	0.9900
6:125045202:ATCAT:A	acceptor_gain	0.9900
6:125045203:T:G	acceptor_gain	0.9900
6:125045315:GTA:G	donor_gain	0.9900

AlphaMissense

3499 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:124963331:T:C	C263R	1.000
6:124963333:C:G	C263W	1.000
6:124963400:T:C	C286R	1.000
6:125045238:T:A	C304S	1.000
6:125045238:T:C	C304R	1.000
6:125045239:G:C	C304S	1.000
6:125045364:T:A	C346S	1.000
6:125045364:T:C	C346R	1.000
6:125045365:G:A	C346Y	1.000
6:125045365:G:C	C346S	1.000
6:125045366:T:G	C346W	1.000
6:125045373:T:C	C349R	1.000
6:125057948:T:C	C375R	1.000
6:125057957:T:C	C378R	1.000
6:125057969:T:A	W382R	1.000
6:125057969:T:C	W382R	1.000
6:125057971:G:C	W382C	1.000
6:125057971:G:T	W382C	1.000
6:125057972:T:A	C383S	1.000
6:125057972:T:C	C383R	1.000
6:125057973:G:C	C383S	1.000
6:125057974:T:G	C383W	1.000
6:125057981:T:A	C386S	1.000
6:125057981:T:C	C386R	1.000
6:125057982:G:C	C386S	1.000
6:125057993:T:A	W390R	1.000
6:125057993:T:C	W390R	1.000
6:125057996:C:G	H391D	1.000
6:125058011:T:A	C396S	1.000
6:125058011:T:C	C396R	1.000

dbSNP variants (sampled 300 via entrez): RS1000022077 (6:124971361 A>C), RS1000114160 (6:125065021 A>G), RS1000116164 (6:125081105 A>G), RS1000124707 (6:125012101 G>A,T), RS1000153291 (6:125014016 T>C), RS1000175039 (6:124988237 A>G,T), RS1000179669 (6:125036189 T>G), RS1000204787 (6:124988561 A>G), RS1000227340 (6:124996251 T>A), RS1000250002 (6:125018507 C>T), RS1000289984 (6:124983446 C>A,G), RS1000309926 (6:125024666 G>A), RS1000316364 (6:125039228 A>C,G,T), RS1000322019 (6:125062258 G>A), RS1000361672 (6:125032218 A>G)

Disease associations

OMIM: gene MIM:618592 | disease phenotypes: MIM:126200

GenCC curated gene-disease

Mondo (1): multiple sclerosis, susceptibility to (MONDO:0007462)

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

1 associations (top):

Study	Trait	p-value
GCST005790_71	Rosacea symptom severity	8.000000e-06

EFO canonical traits (1, from GWAS)

EFO ID	Trait name
EFO:0009180	rosacea severity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

26 total (human), top 26 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	4
bisphenol A	affects methylation, affects cotreatment, decreases expression	2
trichostatin A	increases expression	2
sodium arsenite	decreases expression, increases expression	2
potassium chromate(VI)	affects cotreatment, decreases expression	2
mercuric bromide	increases expression, affects cotreatment	2
belinostat	increases expression, affects cotreatment	2
Panobinostat	affects cotreatment, increases expression	2
Phenylmercuric Acetate	affects cotreatment, increases expression	2
aristolochic acid I	decreases expression	1
methylmercuric chloride	decreases expression	1
epigallocatechin gallate	affects cotreatment, decreases expression	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression	1
2-methyl-2H-pyrazole-3-carboxylic acid (2-methyl-4-o-tolylazophenyl)amide	increases expression, affects cotreatment	1
dorsomorphin	affects cotreatment, increases expression	1
jinfukang	affects cotreatment, decreases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, affects methylation	1
Benzo(a)pyrene	increases methylation	1
Cisplatin	affects cotreatment, decreases expression	1
Tetrachlorodibenzodioxin	affects cotreatment, increases expression	1
Cyclosporine	increases expression	1
Asbestos, Crocidolite	decreases methylation	1
Okadaic Acid	decreases expression	1

Clinical trials (associated diseases)

33 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT06384976	PHASE2	ACTIVE_NOT_RECRUITING	KYSA-7: A Study of Anti-CD19 CAR T-Cell Therapy, in Subjects With Refractory Primary and Secondary Progressive Multiple Sclerosis
NCT06782724	PHASE2	RECRUITING	Psilocybin Therapy for Psychological Distress in Palliative Patients
NCT05102682	PHASE1	COMPLETED	Robotics for Mobility Rehabilitation in MS
NCT06999434	PHASE1	RECRUITING	Exploring the Utility of [18F]3F4AP for Demyelination Imaging
NCT00872053	PHASE1/PHASE2	COMPLETED	Effect of Robot-assisted Training on Foot Drop in Multiple Sclerosis
NCT06548620	EARLY_PHASE1	WITHDRAWN	A Study of RD06-04 in Patients With Active Autoimmune Diseases
NCT06775912	EARLY_PHASE1	RECRUITING	Clinical Study on Targeted CD19/BCMA CAR-T Therapy for Autoimmune Diseases
NCT01128075	Not specified	COMPLETED	Treatment Adherence When Using RebiSmart™ in Relapsing Multiple Sclerosis Subjects
NCT01628276	Not specified	COMPLETED	Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study
NCT02490943	Not specified	COMPLETED	A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS
NCT03155334	Not specified	UNKNOWN	Understanding Evaluation of Patient Information Sheets by User Testing Method
NCT03316404	Not specified	COMPLETED	Evaluating Multiple Sclerosis Patients ShOWing A GEnomic Signature of Therapy Response
NCT04095377	Not specified	COMPLETED	Development of Automated Analysis to Electroencephelogram (EEG) Data in Patients Treated at the Sagol Hyperbaric Medicine and Research Center at the Years 2017-2019.
NCT04148313	Not specified	WITHDRAWN	A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis
NCT04379661	Not specified	COMPLETED	SUNLIGHT Study: Online Support Groups for MS to Address COVID-19
NCT04415372	Not specified	ENROLLING_BY_INVITATION	Macromolecular Imaging of White and Gray Matter Pathology in Multiple Sclerosis
NCT04530955	Not specified	UNKNOWN	Transitioning to a Valve-Gated Intrathecal Drug Delivery System (IDDS)
NCT04822623	Not specified	UNKNOWN	Imaging Evaluation of Central Nervous Autoimmune Diseases
NCT05435404	Not specified	COMPLETED	Qualitative Study Patient & Physician Experiences Botox COVID-19
NCT05857280	Not specified	UNKNOWN	EXOPULSE Mollii Suit, Motor Function & Multiple Sclerosis (EXOSEP 2)
NCT05865405	Not specified	ACTIVE_NOT_RECRUITING	A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis
NCT05912595	Not specified	UNKNOWN	EXOPULSE Mollii Suit, Spasticity, Muscular Oxygenation & Multiple Sclerosis (ENNOX 2)
NCT05991297	Not specified	COMPLETED	Effects of Deep Sensory Assisted Rehabilitation on Gait and Balance in Patients With Multiple Sclerosis
NCT06143930	Not specified	UNKNOWN	Blood Flow Restriction Training in Multiple Sclerosis
NCT06199219	Not specified	COMPLETED	Ex-Plissit Model Based Counseling on Sexual Function and Sexual Satisfaction
NCT06770959	Not specified	NOT_YET_RECRUITING	Frequency of Gastrointestinal and Hepatic Manifestations Among Patients with Multiple Sclerosis, a Clinical Hospital Based Study
NCT06849882	Not specified	RECRUITING	Dubousset Functional Test: an Investigation of Its Validity and Reliability in Individuals with Multiple Sclerosis
NCT07087873	Not specified	RECRUITING	Assessment of Transcranial Alternating Current Stimulation’s Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
NCT07202195	Not specified	RECRUITING	At Home Use of Stimulation Suits for Managing MS Symptoms
NCT07222618	Not specified	RECRUITING	Selfie Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
NCT07235644	Not specified	ACTIVE_NOT_RECRUITING	Comparison of Efficacy and Safety in Patients Switching From MabThera® to Rixathon® in Relapsing-Remitting Multiple Sclerosis
NCT07304960	Not specified	NOT_YET_RECRUITING	Multiple Sclerosis Versus Neuromyelitis Optica Spectrum Disorder
NCT07521384	Not specified	ENROLLING_BY_INVITATION	Real World Outcomes of Intranasal MuSE Exosomes and Stem Cells in Neurological Regenerative Therapy